Articles From: Merck Announces Pricing of Tender Offers for Eight Series of Notes to Mercury General Corporation Announces Agreement to Acquire Workmen's Auto Insurance Company


Merck & Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed below (collectively, the “Notes”). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct.
Sign-up for Merck Announces Pricing of Tender Offers for Eight Series of Notes investment picks
Merck & Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of a public offering of three series of Euro denominated senior unsecured notes due 2021, 2026 and 2034 (collectively, the “New Notes”). The exact terms and timing of the offering will depend upon market conditions and other factors.
Sign-up for Merck Announces Proposed Public Debt Offering investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-naïve and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection --
Sign-up for Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients investment picks
Merck & Co., Inc. (“Merck”) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed below (collectively, the “Notes”). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct.
Sign-up for Merck Announces Tender Offers for Eight Series of Notes investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint.
Sign-up for Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2014.
Sign-up for Merck Announces Third-Quarter 2014 Financial Results investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has completed the previously announced sale of the Merck Consumer Care (MCC) business to Bayer AG.
Sign-up for Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the government of Ecuador on being the second country in the world to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis) using MECTIZAN ® (ivermectin). Ecuador worked in partnership with the MECTIZAN Donation Program and The Carter Center-sponsored Onchocerciasis Elimination Program for the Americas, as well as the Pan American Health Organization, the Regional Office for the Americas of the World Health Organization (PAHO/WHO), to eliminate onchocerciasis – one of the leading causes of preventable blindness worldwide.
Sign-up for Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness investment picks
2014/11/24
By Peter Loftus Merck & Co.
Sign-up for Merck obtains right to experimental Ebola vaccine investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes.
Sign-up for Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes investment picks
Merck & Co., Inc. (the “Company”) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the “New Notes”). Based on Oct.
Sign-up for Merck Prices EUR 2.5 Billion Debt Offering investment picks
2014/12/9
By Chelsey Dulaney Merck & Co.
Sign-up for Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling investment picks
2014/12/9
By Chelsey Dulaney Drug maker Merck & Co.
Sign-up for Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy.
Sign-up for Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer investment picks
2014/12/9
Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware.
Sign-up for Merck Statement Regarding CUBICIN Patent Litigation investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). “Merck is committed to helping patients with type 2 diabetes and we are excited about the submission of the new drug application for omarigliptin in Japan,” said Peter Stein, M.D., vice president, clinical research, diabetes and endocrinology, Merck Research Laboratories.
Sign-up for Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.
Sign-up for Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash investment picks
2014/12/8
By Peter Loftus and Dana CimillucaThe per-share bid of $102 is 37% above Friday's closing price of Cubist's stock Drug giant Merck & Co.
Sign-up for Merck to buy Cubist Pharmaceuticals for $8.4 billion investment picks
2014/12/8
By Peter Loftus And Dana Cimilluca Merck & Co.
Sign-up for Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 3rd Update investment picks
2014/12/8
By Peter Loftus And Dana Cimilluca Merck & Co.
Sign-up for Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update investment picks
2014/12/8
By Peter Loftus And Dana Cimilluca Merck & Co.
Sign-up for Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update investment picks
2014/12/8
By Peter Loftus and Dana Cimilluca Merck & Co.
Sign-up for Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update investment picks
Cubist Pharmaceuticals (CBST) announced on Monday an agreement to be acquired by Merck & Co.
Sign-up for Merck to buy Cubist Pharmaceuticals in $9.5 billion deal investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Monday, Oct.
Sign-up for Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65 th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting ® .
Sign-up for Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting investment picks
2014/11/10
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Two drug makers on vastly different paths both found themselves in negative territory Monday, as Dow component Merck & Co.
Sign-up for Merck, Dendreon miss out on health-care rally investment picks
Merck (MRK) and NewLink Genetics Corp.
Sign-up for Merck, NewLink to collaborate on Ebola vaccine investment picks
Collective Voice of Community Embodies Culmination of "Getting Vocal" About Individualized Treatment around the Country WHITEHOUSE STATION, N.J. , Dec.
Sign-up for Merck's HIV Education Campaign, I Design, Reveals Video and Poem Created by the HIV Community in Honor of World AIDS Day investment picks
2014/12/3
By Sarah Kent LONDON---
Sign-up for Mercuria Says Citigroup Tried to Force It Into Early Repayment in Repo Deal investment picks
2014/10/23
LOS ANGELES , Oct.
Sign-up for Mercury General Corporation Announces Agreement to Acquire Workmen's Auto Insurance Company investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Merck Announces Pricing of Tender Offers for Eight Series of Notes to Mercury General Corporation Announces Agreement to Acquire Workmen's Auto Insurance Company
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent